We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+1.02%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.53B
AUM Growth
-$1.13M
Cap. Flow
+$46.2M
Cap. Flow %
3.01%
Top 10 Hldgs %
22.12%
Holding
1,502
New
414
Increased
344
Reduced
260
Closed
396

Sector Composition

Rank Sector Weight
1 Technology 14.68%
2 Healthcare 10.56%
3 Consumer Discretionary 9.55%
4 Industrials 7.76%
5 Energy 6.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CDIO icon
1051
Cardio Diagnostics
CDIO
$5.06M
$41.1K ﹤0.01%
4,033
+366
+10% +$8.8K
ADV icon
1052
Advantage Solutions
ADV
$383M
$39K ﹤0.01%
+549
New +$36.4K
DZSI
1053
DELISTED
DZS Inc. Common Stock
DZSI
$38K ﹤0.01%
+18,100
New +$52K
DRRX
1054
DELISTED
DURECT Corp
DRRX
$37.6K ﹤0.01%
15,081
+3,793
+34% +$12.9K
RMNI icon
1055
Rimini Street
RMNI
$458M
$36.3K ﹤0.01%
16,512
-6,778
-29% -$20.6K
SLDP icon
1056
Solid Power
SLDP
$536M
$35.4K ﹤0.01%
17,500
-9,300
-35% -$22K
ALT icon
1057
Altimmune
ALT
$593M
$32.8K ﹤0.01%
+12,600
New +$36.1K
ZH
1058
Zhihu
ZH
$284M
$31.6K ﹤0.01%
+5,064
New +$33.1K
SRZN icon
1059
Surrozen
SRZN
$295M
$30.2K ﹤0.01%
4,113
ERAS icon
1060
Erasca
ERAS
$6.29B
$28.2K ﹤0.01%
14,300
DCFC
1061
CALL
DELISTED
Tritium DCFC Limited Ordinary Shares
DCFC
$26.5K ﹤0.01%
+438
New +$83.4K
CVIIW
1062
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$25.9K ﹤0.01%
84,235
-113,775
-57% -$27.8K
KDKRW
1063
Kodiak AI Warrants
KDKRW
$23.6K ﹤0.01%
+100,590
New +$29.2K
CANO
1064
DELISTED
Cano Health, Inc.
CANO
$21.5K ﹤0.01%
846
+581
+219% +$47.8K
NKTX icon
1065
Nkarta
NKTX
$176M
$20.8K ﹤0.01%
14,929
-700
-4% -$1.33K
PYXS icon
1066
Pyxis Oncology
PYXS
$243M
$20.6K ﹤0.01%
10,352
SNDL icon
1067
CALL
Sundial Growers
SNDL
$318M
$19.8K ﹤0.01%
10,400
BCAB icon
1068
BioAtla
BCAB
$5.76M
$18.8K ﹤0.01%
222
-98
-31% -$12.5K
ASTLW icon
1069
Algoma Steel Group Warrant
ASTLW
$314K
$15K ﹤0.01%
12,313
NBSE
1070
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$13.5K ﹤0.01%
15,550
GHIXW
1071
DELISTED
Gores Holdings IX, Inc. Warrant
GHIXW
$13.1K ﹤0.01%
65,440
SCRMW
1072
DELISTED
Screaming Eagle Acquisition Corp. Warrant
SCRMW
$13.1K ﹤0.01%
76,862
-237,110
-76% -$42.9K
YOTAR
1073
DELISTED
Yotta Acquisition Corporation Right
YOTAR
$11.9K ﹤0.01%
100,000
VANI icon
1074
Vivani Medical
VANI
$122M
$11.2K ﹤0.01%
10,996
CCVI.WS
1075
DELISTED
Churchill Capital Corp VI Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCVI.WS
$8.9K ﹤0.01%
55,638
+26,933
+94% +$4.9K

Similar funds

Prelude Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Prelude Capital Management held 1,502 positions worth $1.53B, down 0.07% from $1.54B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Prelude Capital Management deployed $46.2M of net new capital in Q3 2023, opening 414 new positions and adding to 344 existing holdings. Its largest new stake was New Relic, Inc.: 130,823 shares worth $11.2M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was iShares Russell 2000 ETF, an estimated $38.6M trimmed.

  • Prelude Capital Management's largest Q3 2023 buy was New Relic, Inc.: 130,823 shares worth $11.2M.
  • Prelude Capital Management added most to Alibaba in Q3 2023, an estimated $10.4M increase.
  • Prelude Capital Management's biggest Q3 2023 reduction was iShares Russell 2000 ETF, cutting an estimated $38.6M.
  • Prelude Capital Management fully exited Green Brick Partners in Q3 2023, selling an estimated $48.6M.
  • Prelude Capital Management's ten largest holdings make up 22% of its $1.53B portfolio in Q3 2023.
  • Prelude Capital Management opened 414 new positions and closed 396 in Q3 2023.
  • Prelude Capital Management's portfolio value fell 0.07% quarter-over-quarter to $1.53B.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.